Signal transduction networks in cancer: Quantitative parameters influence network topology

Cancer Research

Volumn 70, Issue 5, 2010, Pages 1773-1782

  Klinke II, David J ^a,b  

^a West Virginia University   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; MULTIPROTEIN COMPLEX; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP;

ARTICLE; BAYES THEOREM; BINDING AFFINITY; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CORRELATION ANALYSIS; MATHEMATICAL MODEL; NEOPLASM; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CALIBRATION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN INTERACTION MAPPING; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; THERMODYNAMICS;

EID: 77950223515     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3234     Document Type: Article

References (41)

1. Jones RB, Gordus A, Krall JA, MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 2006;439:168-174
2. Kaushansky A, Gordus A, Chang B, Rush J, MacBeath G. A quantitative study of the recruitment potential of all intracellular tyrosine residues on EGFR, FGFR1 and IGF1R. Mol Biosyst 2008;4:643-653
3. Asthagiri AR, Lauffenburger DA. Bioengineering models of cell signaling. Ann Rev Biomed Eng 2000;2:31-53.
4. Schlessinger J. Epidermal growth factor receptor pathway. science signaling. (Connections Map in the Database of Cell Signaling, as seen 28 July 2009); http://stke.sciencemag.org/cgi/cm/stkecm;CMP-14987.
5. Schulze WX, Deng L, Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 2005;1:8.
6. Gaudet S, Janes KA, Albeck JG, Pace EA, Lauffenburger DA, Sorger PK. A compendium of signals and responses triggered by prodeath and prosurvival cytokines. Mol Cell Proteomics 2005;4:1569-1590
7. Birtwistle MR, Hatakeyama M, Yumoto N, Ogunnaike BA, Hoek JB, Kholodenko BN. Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses. Mol Syst Biol 2007;3:144.
8. Kholodenko BN, Demin OV, Moehren G, Hoek JB. Quantification of short term signaling by the epidermal growth factor receptor. J Biol Chem 1999;274:30169-30181
9. Bruggeman FJ, Snoep JL, Westerhoff HV. Control, responses and modularity of cellular regulatory networks: a control analysis perspective. IET Syst Biol 2008;2:397-410.
10. Kholodenko BN, Hoek JB, Westerhoff HV, Brown GC. Quantification of information transfer via cellular signal transduction pathways. FEBS Lett 1997;414:430-434
11. Papin JA, Palsson BO. Topological analysis of mass-balanced signaling networks: a framework to obtain network properties including crosstalk. J Theor Biol 2004;227:283-297
12. Stelling J, Sauer U, Szallasi Z, Doyle FJ III, Doyle J. Robustness of cellular functions. Cell 2004;118:675-685
13. Barkai N, Leibler S. Robustness in simple biochemical networks. Nature 1997;387:913-917
14. Pawson T, Warner N. Oncogenic re-wiring of cellular signaling pathways. Oncogene 2007;26:1268-1275
15. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-125
16. Hogervorst FBL, Nederlof M, Gille JJP, et al. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res 2003;63:1449-1453
17. Miklos GLG. The human cancer genome project: one more misstep in the war on cancer. Nat Biotechnol 2005;23:535-537
18. Nobeli I, Favia AD, Thornton JM. Protein promiscuity and its implications for biotechnology. Nat Biotechnol 2009;27:157-167
19. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-527
20. Gangnus R, Langer S, Breit E, Pantel K, Speicher MR. Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clin Cancer Res 2004;10:3457-3464
21. Irish JM, Hovland R, Krutzik PO, et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004;118:217-228
22. Miller WE, Raab-Traub N. The EGFR as a target for viral oncoproteins. Trends Microbiol 1999;7:453-458
23. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2006;12:7261-7270
24. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-3167
25. Breitling R, Hoeller D. Current challenges in quantitative modeling of epidermal growth factor signaling. FEBS Lett 2005;579:6289-6294
26. Gordus A, Krall JA, Beyer EM, et al. Linear combinations of docking affinities explain quantitative differences in RTK signaling. Mol Sys Biol 2009;5:235.
27. Jacquez JA, Perry T. Parameter estimation: local identifiability of parameters. Am J Physiol 1990;258:E727-36.
28. Klinke DJ. An age-structured model of dendritic cell trafficking in the lung. Am J Physiol Lung Cell Mol Physiol 2006;291:L1038-49.
29. Green WH. Predictive kinetics: a new approach for the 21st century. Adv Chem Eng 2007;32:1-50.
30. Klinke DJ. An empirical Bayesian approach for model-based inference of cellular signaling networks. BMC Bioinform 2009;10:371.
31. Reddy CC, Wells A, Lauffenburger DA. Receptor-mediated effects on ligand availability influence relative mitbgenic potencies of epidermal growth factor and transforming growth factor α. J Cell Physiol 1996;166:512-522
32. Aronheim A, Engelberg D, Li N, al Alawi N, Schlessinger J, Karin M. Membrane targeting of the nucleotide exchange factor Sos is sufficient for activating the Ras signaling pathway. Cell 1994;78:949-961
33. Mulcahy LS, Smith MR, Stacey DW. Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells. Nature 1985;313:241-243
34. ras GTP in response to stimulation with epidermal growth factor and oncogene products with tyrosine kinase activity. Proc Natl Acad Sci U S A 1990;87:7926-7929
35. Klinke DJ, Broadbelt LJ. Mechanism reduction during computer generation of compact reaction models. AIChE J 1997;43:1828-1837
36. Huang CY, Ferrell JE, Jr. Ultrasensitivity in the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A 1996;93:10078-10083
37. Westerhoff HV. Signalling control strength. J Theor Biol 2008;252:555-567
38. Shi Y, Wang R, Sharma A, et al. Dissociation of cytokine signals for proliferation and apoptosis. J Immunol 1997;159:5318-5328
39. Dearth RK, Cui XJ, Kim HJ, et al. Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Mol Cell Biol 2006;26:9302-9314
40. Weinberg RA. The Biology of Cancer. New York: Garland Science; 2007, p. 159.
41. Le Novere N, Moodie S, Sorokin A, et al. The systems biology graphical notation. Nat Biotech 2009;27:735-741